JP7839260B2 - 糖尿病性腎症の処置のためのｉｌ１ｒａ由来ペプチド - Google Patents

糖尿病性腎症の処置のためのｉｌ１ｒａ由来ペプチド

Info

Publication number
JP7839260B2
JP7839260B2 JP2024501194A JP2024501194A JP7839260B2 JP 7839260 B2 JP7839260 B2 JP 7839260B2 JP 2024501194 A JP2024501194 A JP 2024501194A JP 2024501194 A JP2024501194 A JP 2024501194A JP 7839260 B2 JP7839260 B2 JP 7839260B2
Authority
JP
Japan
Prior art keywords
amino acid
compound
seq
peptide
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024501194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525669A5 (https=
JP2024525669A (ja
Inventor
スタイネス，エヴァ
Original Assignee
セロダス エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セロダス エーピーエス filed Critical セロダス エーピーエス
Publication of JP2024525669A publication Critical patent/JP2024525669A/ja
Publication of JP2024525669A5 publication Critical patent/JP2024525669A5/ja
Application granted granted Critical
Publication of JP7839260B2 publication Critical patent/JP7839260B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024501194A 2021-07-13 2021-07-13 糖尿病性腎症の処置のためのｉｌ１ｒａ由来ペプチド Active JP7839260B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/069450 WO2023284947A1 (en) 2021-07-13 2021-07-13 Il1ra derived peptides for treatment of diabetic nephropathy

Publications (3)

Publication Number Publication Date
JP2024525669A JP2024525669A (ja) 2024-07-12
JP2024525669A5 JP2024525669A5 (https=) 2024-07-23
JP7839260B2 true JP7839260B2 (ja) 2026-04-01

Family

ID=76958978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501194A Active JP7839260B2 (ja) 2021-07-13 2021-07-13 糖尿病性腎症の処置のためのｉｌ１ｒａ由来ペプチド

Country Status (8)

Country Link
US (1) US20240216464A1 (https=)
EP (1) EP4351617B1 (https=)
JP (1) JP7839260B2 (https=)
CN (1) CN117642174A (https=)
AU (1) AU2021455992A1 (https=)
CA (1) CA3226176A1 (https=)
ES (1) ES3026437T3 (https=)
WO (1) WO2023284947A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510082A (ja) 2011-03-14 2014-04-24 セロドウス アーエスアー インターロイキン−１受容体のアンタゴニスト
WO2017063657A1 (en) 2015-10-14 2017-04-20 Phlogo Aps Il1ra-derived peptide antagonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
KR101317045B1 (ko) * 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
WO2018022982A1 (en) * 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510082A (ja) 2011-03-14 2014-04-24 セロドウス アーエスアー インターロイキン−１受容体のアンタゴニスト
WO2017063657A1 (en) 2015-10-14 2017-04-20 Phlogo Aps Il1ra-derived peptide antagonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kidney Int，2014年06月30日，vol. 87(1)，pp. 74-84
SER140 is a peptide with anti-inflammatory properties, [online]，Serodus，2021年04月19日，<URL: https://web.archive.org/web/20210419192221/https://serodus.com/ser140/ >, [retrieved on 2025.07.24] which retrieved from the internet

Also Published As

Publication number Publication date
AU2021455992A1 (en) 2024-01-18
CA3226176A1 (en) 2023-01-19
EP4351617B1 (en) 2025-03-26
WO2023284947A1 (en) 2023-01-19
EP4351617C0 (en) 2025-03-26
JP2024525669A (ja) 2024-07-12
EP4351617A1 (en) 2024-04-17
ES3026437T3 (en) 2025-06-11
US20240216464A1 (en) 2024-07-04
CN117642174A (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
Takashima et al. Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
ES2651268T3 (es) Composiciones que contienen alfa-1-antitripsina y métodos para su uso
CN102389413B (zh) 用于治疗糖尿病的组合物及其应用
TW200817431A (en) Diuretic and natriuretic polypeptides
KR20170023066A (ko) 글루카곤 수용체 길항 항체를 이용한 제 1 형 당뇨병의 치료 방법
JP2019527192A (ja) 全身性エリテマトーデスの診断及び治療方法
Chai et al. Targeting the CDA1/CDA1BP1 axis retards renal fibrosis in experimental diabetic nephropathy
AU2010202600B2 (en) A novel peptide involved in energy homeostasis
US20170216244A1 (en) Methods for treating diabetic nephropathy
JP7839260B2 (ja) 糖尿病性腎症の処置のためのｉｌ１ｒａ由来ペプチド
Kim et al. Long-term blockade of vascular endothelial growth factor receptor-2 aggravates the diabetic renal dysfunction associated with inactivation of the Akt/eNOS-NO axis
JP2021529793A (ja) リウマチ関節炎治療用ペプチド及びその用途
EP4041281B1 (en) Use of gdf15 for treating cardiometabolic syndrome and other conditions
TW202417033A (zh) 腎臟結石的治療或預防劑
JP7634138B1 (ja) 糖尿病性腎症の治療における使用のためのｉｌ－４由来ペプチド断片
CN113748123B (zh) 用于治疗肺部炎症的组合物
CA3244198C (en) Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy
KR20260040257A (ko) Hb-egf/egfr 경로 활성화와 관련된 신장 질환치료에서 사용하기 위한 hb-egf 억제제 및 코르티코스테로이드 제제의 조합
WO2017063657A1 (en) Il1ra-derived peptide antagonist
Lee Insulin-Independent Regulation of Type 1 Diabetes via Large Brown Adipocyte-Secreted Proteins and the Novel Glucagon Regulator, Nidogen2
WO2017165515A1 (en) Stimulation of bone growth using apolipoprotein e
Wang et al. Characterization of the Active Components of the Multimerized sTNFRII-Adiponectin Fusion Protein Showing Both TNFα-Antagonizing and Glucose Uptake-Promoting Activities
Zhao et al. FP017 Critical Equilibrium between CCL2 Secretion and Its Constitutive Re-Uptake by CCR2: An Elegant Mechanism for Regulating CCL2 Levels in the Blood
US20200270335A1 (en) Dkk2 cysteine rich domain 2 containing proteins and uses thereof
Singal et al. Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Diabetic Complications

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20240301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260319

R150 Certificate of patent or registration of utility model

Ref document number: 7839260

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150